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OBJECTIVES We sought to determine the electrophysiologic actions of sotalol in the remodeled atrium of
humans.
BACKGROUND In experimental studies, sotalol has limited class III action in the electrically remodeled atrium
and did not prevent atrial fibrillation (AF) induction.
METHODS We determined the effective refractory periods (ERPs) at three pacing cycle lengths (400, 500,
and 600 ms) in the high right atrium (HRA) and distal coronary sinus (DCS) before and after
intravenous infusion of dl-sotalol in 10 patients with persistent AF who underwent internal
cardioversion. The same protocols were performed in 10 control subjects in sinus rhythm.
RESULTS In the HRA and DCS, the atrial ERPs at different drive cycle lengths were significantly
shorter in patients with AF than in control subjects (p 0.05). In patients with AF, the atrial
ERP’s adaptation to rate was nearly normal in the HRA, but was poor in the DCS. In both
groups, dl-sotalol significantly increased the atrial ERPs at both the HRA and DCS, as
compared with baseline (p  0.05). However, the prolongation of atrial ERPs was
significantly less at a drive cycle length of 600 ms in patients with AF versus control subjects
(p  0.05). After infusion of dl-sotalol, the atrial ERP’s adaptation to rate at both the HRA
and DCS was poor in patients with AF, and AF was still easily inducible in the majority of
them, but not in control subjects.
CONCLUSIONS The results of the present study demonstrate that the electrophysiologic actions of dl-sotalol
are significantly attenuated in the chronically remodeled human atrium, and these changes
might represent a probable explanation for the low efficacy of dl-sotalol to prevent early AF
recurrence after electrical cardioversion. (J Am Coll Cardiol 2002;40:2150–5) © 2002 by
the American College of Cardiology Foundation
Experimental and clinical studies have shown that atrial
fibrillation (AF) resulted in electrical remodeling of the
atrium and increased the susceptibility to further episodes of
AF (1–4). Although these electrophysiologic changes ap-
peared to be reversible after restoration and maintenance of
sinus rhythm (5,6), they might affect the efficacy of anti-
arrhythmic agents in preventing early AF recurrence. De-
spite the use of anti-arrhythmic therapy, AF frequently
recurs within the first two weeks after electrical cardiover-
sion (7,8).
Sotalol is a class III anti-arrhythmic agent commonly
used in patients with AF. It prolongs the atrial action
potential duration by blocking the delayed rectifier potas-
sium channel (IKr) (9), but its effect declines at a rapid rate
with reverse-use dependency (10,11). Recent animal studies
revealed that sotalol exerted a limited class III effect during
AF in the remodeled atrium and failed to prolong the atrial
refractory period after cardioversion of persistent AF
(12,13). Although the mechanism remains unclear, these
studies suggested that AF-induced atrial electrical remod-
eling might affect the electrophysiologic actions of anti-
arrhythmic agents on the atrium. No previous studies have
examined the effects of sotalol in the remodeled atrial
myocardium of humans. Therefore, the aim of the present
study was to assess the effect of sotalol on atrial refractori-
ness in humans after electrical cardioversion of persistent
AF.
METHODS
Patients. The study included 10 patients with persistent
AF (duration between three months and three years) ad-
mitted for internal cardioversion. The diagnosis of AF was
based on the surface electrocardiogram (ECG), which
showed a fluctuation from baseline without regular P or F
waves and with totally irregular RR intervals. All patients
were evaluated by taking a detailed clinical history and
physical examination, as well as relevant laboratory investi-
gations such as a thyroid function test and transthoracic
echocardiography. They were anticoagulated with warfarin
to achieve an International Normalized Ratio (INR) of 2 to
3 for at least four weeks. All anti-arrhythmic drugs were
discontinued for at least five half-lives. No patients received
amiodarone within six months before the study. Patients
with the following conditions were excluded from the study:
1) AF due to reversible causes; 2) unstable angina or
myocardial infarction within six months; 3) class III or IV
heart failure; 4) history of thromboembolism within six
months; 5) corrected QT interval 450 ms; 6) contraindi-
cations or previous intolerance to sotalol; and 7) inability to
complete the study protocol because of either failure in
cardioversion or frequent, sustained AF (3 episodes)
induced or occurring spontaneously during electrophysi-
ologic study, requiring repeat cardioversion.
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Ten age-matched patients with supraventricular tachy-
cardia (three with atrioventricular node reentry tachycardia
and seven with atrioventricular reciprocating tachycardia)
were included as the control group. These patients had no
structural heart disease and no clinical atrial flutter or
fibrillation.
Electrophysiologic study. All patients underwent instru-
mentation with two custom-built 6F decapolar catheters
(Elacath Inc., Rahway, New Jersey) for internal cardiover-
sion and/or electrophysiologic study. Each catheter has five
pairs of stainless-steel rings with 2-mm interelectrode spac-
ing within each pair and 5-mm spacing between each pair.
One catheter was positioned along the high (anterolateral)
right atrium (HRA), and the other was advanced into the
distal coronary sinus (DCS). An additional quadripolar
electrode catheter was placed in the right ventricular apex
for shock synchronization. Surface ECG leads II and V1
and intracardiac electrograms from HRA and DCS were
displayed on an oscilloscope and recorded at a paper speed
of 100 mm/s (PPG, MIDAS 5000, Lenexa, Kansas). Pacing
was performed with a programmable stimulator (EP3,
EPMedSystem, New Jersey).
Study protocol. The study was approved by our Institu-
tional Ethical Committee, and all the patients gave written,
informed consent. In all patients with persistent AF, inter-
nal cardioversion was performed by using an external atrial
defibrillator (XAD, InControl, Inc., Redmond, Washing-
ton) capable of delivering R-wave–synchronized biphasic
shocks (3-ms/3-ms waveform) of up to 6 J, as described
previously (14). After restoration of sinus rhythm, a 15-min
waiting period was observed to allow short-term, rate-
related changes in the atrial effective refractory period
(ERP) to dissipate (15). In the control group, the study
protocol was performed after completion of the radiofre-
quency ablation procedure.
A pair of bipolar electrodes from each of the HRA and
DCS catheters was selected for programmed stimulation, so
that the pacing threshold was 1.0 mA (mean atrial pacing
threshold of 0.8  0.1 mA). Pacing was performed at twice
the diastolic stimulation threshold using a 2-ms pulse
duration. The atrial pacing threshold at each site was then
verified at the end of the stimulation protocol. When a
significant difference in the pacing threshold was found
(0.5 mA), the data were not considered for analysis; either
another pair of electrodes was selected or the catheter was
repositioned, and the stimulation protocol repeated. At the
HRA and DCS, the atrial ERP was measured at basic cycle
lengths of 400, 500, and 600 ms, with drive train of 8 beats
and a 3-s pause between pacing trains, in random order.
The initial S1–S2 interval was set to be shorter than the
atrial ERP, and the S1–S2 interval was increased in steps of
5 ms until there was atrial capture. The atrial ERP was
defined as the longest S1–S2 interval that failed to result in
atrial capture. The atrial ERP were measured twice at each
drive cycle length and averaged. Patients who developed
sustained AF (10 min) during the determination of atrial
ERPs were internally cardioverted. Patients with more than
three episodes of sustained, secondarily induced AF were
excluded from the analysis. Because short episodes of AF
can affect atrial refractoriness for several minutes (16), the
study protocol was suspended for 15 min after spontaneous
or electrical cardioversion.
After the baseline atrial ERP measurement, an intrave-
nous infusion of dl-sotalol (1.5 mg/kg body weight for the
loading dose over 10 min and 0.2 mg/kg per h for
maintenance) was administrated to all patients. Ten min-
utes after the loading dose was given, the atrial ERP was
measured, as in the baseline study.
Statistical analysis. Continuous data are presented as the
mean value  SD. Nonparametric data were analyzed by
the chi-square test with Yates’ correction or by the Fisher
exact test. The atrial ERP measurements at baseline and
after sotalol infusion at different basic cycle lengths were
analyzed by analysis of variance with repeated measures. In
the HRA and DCS, the linear correlation between the
ERPs and corresponding pacing cycle lengths was calcu-
lated by single linear regression. The presence of normal or
abnormal ERP’s adaptation to rate and its degree were also
determined by measurement of the slope values, as de-
scribed previously (5). When a negative or positive slope
value was between 0.01 and 0.04, the adaptation were poor;
between 0.05 and 0.06, it was considered as nearly normal;
and 0.7, it was classified as normal. The paired Student t
test was used to compare the change in ERP after anti-
arrhythmic drug administration. A value of p  0.05 was
considered as statistically significant.
RESULTS
Patients. There were eight men and two women with AF
(mean [SD] age 59  12 years). Their mean AF duration
was 198  360 days (range 90 to 1,440). Their mean left
ventricular ejection fraction was 0.61  0.11, and their left
atrial diameter was 40.6  6.3 mm (range 38 to 54).
Underlying heart disease was present in six patients: hyper-
tension (n  4), valvular heart disease (n  1), and dilated
cardiomyopathy (n  1). Four patients had only AF. In the
control subjects, there were seven men and three women
(mean age 57  10 years). Their mean left ventricular
ejection fraction was 0.67  0.09, and their left atrial
diameter was 32.5  4.2 mm. Patients with AF had a
significantly larger left atrial size (p  0.01) and a lower left
ventricular ejection fraction (p  0.05) as compared with
control subjects.
Abbreviations and Acronyms
AF  atrial fibrillation
DCS  distal coronary sinus
ERP  effective refractory period
HRA  high right atrium
IKr  delayed rectifier potassium channel
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The ERP’s adaptation to rate. The mean atrial ERPs
measured in the HRA and DCS in both patients with AF
and control subjects are reported in Table 1. The atrial
ERPs at drive cycle lengths of 400, 500, and 600 ms in the
HRA and DCS were significantly shorter in patients with
AF than in control subjects.
As shown in Figure 1, there was a linear correlation
between the mean atrial ERPs and the drive cycle lengths in
the HRA (r  0.94, mean slope value 0.06  0.03), but not
in the DCS (r  0.46, mean slope value 0.02  0.05) in
patients with AF. In the control subjects, there was a linear
correlation between the mean atrial ERPs and the drive
cycle lengths in the HRA (r  0.96, mean slope value
0.08  0.02) and in the DCS (r  0.93, mean slope value
0.09  0.04). Therefore, a nearly normal adaptation of the
atrial ERPs to the rate was present in the HRA but not in
the DCS in patients with AF.
Effects of dl-sotalol on ERPs. In both patients with AF
and control subjects, dl-sotalol significantly increased the
mean atrial ERPs measured in both the HRA and DCS at
different drive cycle lengths, as compared with baseline (all
p  0.05 vs. baseline) (Table 1). The mean prolongation of
atrial ERPs at the HRA and DCS in both patients with AF
and control subjects after infusion of dl-sotalol is shown in
Figure 2. In patients with AF, there were no significant
differences in the prolongation of atrial ERPs in the HRA
and DCS with an increasing drive cycle length (p  0.05).
In control subjects, the prolongation of atrial ERPs in the
HRA and DCS after infusion of dl-sotalol increased with
lengthening of the drive cycle length from 400 to 600 ms (p
 0.05). As a result, the prolongation of atrial ERPs in the
HRA and DCS at a drive cycle length of 600 ms was
significant longer in control subjects than in patients with
AF (p  0.05). Therefore, a reverse rate–dependent pro-
longation of atrial ERPs, as observed in control subjects
after infusion of dl-sotalol, was absent in patients with AF.
As shown in Figure 1, adaptations of atrial ERPs to the
rate in the HRA (r  0.34, mean slope value 0.03  0.06)
and in the DCS (r  0.56, mean slope value 0.03  0.05)
were poor in patients with AF after infusion of dl-sotalol.
Adaptations of atrial ERPs to the rate in the HRA (r 
0.93, mean slope value 0.09  0.04) and in the DCS (r 
0.95, mean slope value 0.09  0.04) remained normal in
control subjects after infusion of dl-sotalol.
Induction of secondary AF episodes. At baseline, a sec-
ondary episode of AF was induced during 60 (38%) of 160
measurements of atrial ERP in 9 (90%) patients with AF. In
control subjects, secondary AF was induced during 22 (15%)
of 144 measurements of atrial ERPs (p  0.01 vs. patients
with AF) in 4 (40%) patients (p  0.06 vs. patients with
AF).
Table 1. Atrial Effective Refractory Periods at Baseline and After dl-Sotalol Infusion
Baseline After dl-Sotalol
Basic Cycle Length Basic Cycle Length
400 ms 500 ms 600 ms 400 ms 500 ms 600 ms
HRA
Patients with AF 173  28 181  24 185  25 200  23 202  28 205  30
Control subjects 188  14* 195  16* 204  16* 215  14* 227  16* 241  22*
DCS
Patients with AF 183  22 185  24 187  22 207  30 213  32 214  32
Control subjects 201  15† 213  18† 219  20† 231  17† 248  18† 260  19†
*p  0.05 versus patients with AF. †p  0.01 versus patients with AF. Data are presented as the mean value  SD.
AF  atrial fibrillation; DCS  distal coronary sinus; HRA  high right atrium.
Figure 1. Relationship between the pacing cycle length and atrial effective
refractory periods (ERPs) measured in the high right atrium (HRA) (A)
and distal coronary sinus (DCS) (B) in patients with atrial fibrillation (AF)
and control subjects before and after intravenous infusion of dl-sotalol.
Solid squares  control subjects at baseline; solid triangles  patients
with AF at baseline; open squares  control subjects after dl-sotalol
infusion; open triangles  patients with AF after dl-sotalol infusion.
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After infusion of dl-sotalol, a secondary episode of AF was
still induced during 42 (30%) of 141 measurements of atrial
ERP (p  0.2 vs. baseline) in 8 (80%) patients (p  1.0 vs.
baseline). In control subjects, secondary AF was induced
during only 8 (6%) of 132 measurements of atrial ERPs (p 
0.02 vs. baseline; p  0.01 vs. patients with AF) in 2 (20%)
patients (p  0.6 vs. baseline; p  0.02 vs. patients with AF).
The incidences of sustained AF both at baseline (2/22
[9%] vs. 14/60 [23%], p  0.2) and after infusion of
dl-sotalol (1/8 [13%] vs. 12/42 [29%], p 0.7) were similar
in control subjects and patients with AF. Infusion of
dl-sotalol did not reduce the incidence of sustained AF in
either control subjects or patients with AF (p  0.05).
DISCUSSION
Main findings. The results of the present study demon-
strate that the electrophysiologic actions of dl-sotalol were
significantly reduced in the chronically remodeled human
atrium. Compared with the control subjects, infusion of
dl-sotalol in patients with AF resulted in a lesser prolonga-
tion of atrial ERPs at a long drive cycle length and loss of
the reverse-use–dependent property and failed to prevent
induction of secondary AF.
Changes in dl-sotalol action in the remodeled atrium.
Although dl-sotalol has been shown to be effective in
preventing early re-initiation of AF after cardioversion by
suppression of atrial premature beats (14), AF still recurs in
a significant proportion of patients within the first two
weeks (17). The relative lack of efficacy of dl-sotalol in
preventing early AF recurrence remains obscure. dl-Sotalol
has both class II and III anti-arrhythmic effects by its
anti-adrenergic effect and blockage of the IKr channel,
respectively (9). Previous experimental studies have demon-
strated that sotalol showed a dose-dependent prolongation
of atrial ERPs and prevented AF initiation; however, its
effect on atrial ERPs declined at a rapid rate with reverse-
use dependency (10,11). It has been postulated that the
reverse-use–dependent properties of class III agents were
due to the use-dependent accumulation of potassium cur-
rent, which counteracts the use-dependent blockage of the
potassium channel (18). Although the use-dependent prop-
erty of sotalol might limit the efficacy of sotalol in termi-
nating AF, Derakhchan et al. (19) showed that sotalol
prevented AF initiation by atrial premature beats by increas-
ing the atrial ERP at a slower resting sinus rate. Thus, the
use-dependent property might contribute to electrophysi-
ologic mechanism of sotalol for the prevention of AF.
Recently, Wijffels et al. (12,13) demonstrated that sotalol
exerted a limited class III effect and failed to prolong atrial
ERPs both during AF and after cardioversion in a goat
model of persistent AF. These findings suggest that the
electrophysiologic actions of sotalol might be attenuated in
the remodeled atrium. Moreover, in addition to reduced
ERP prolongation by sotalol in the remodeled atrium,
changes in mechanisms underlying AF vulnerability with
remodeling, including increased ERP heterogeneity, could
have contributed to the reduced clinical efficacy of sotalol
(20). Previous experimental studies have demonstrated that
sotalol does not decrease atrial refractory heterogeneity
during AF (21).
This study confirmed that the changes in the electro-
physiologic properties of the remodeled atrium in humans
resulted in shortening and loss of rate adaptation of the
atrial ERP, with more pronounced changes in the DCS
than in the HRA (2,3,6). To our knowledge, this is the first
study to investigate the electrophysiologic actions of dl-
sotalol in the remodeled human atrium. In this study,
patients with long-standing AF were studied to determine
the effect of AF-related atrial remodeling on the electro-
physiologic action of dl-sotalol. Although dl-sotalol also
prolonged the atrial ERP at the HRA and DCS in patients
with AF, prolongation of atrial ERPs at a slower rate was
significantly less than that in control subjects. As a result,
Figure 2. Relationship between the pacing cycle length and prolongation
of atrial effective refractory periods (ERPs) after intravenous infusion of
dl-sotalol in the high right atrium (HRA) (A) and distal coronary sinus
(DCS) (B) in patients with atrial fibrillation (AF) and control subjects.
Data are presented as the mean value  SD of the prolongation of ERPs.
Solid diamonds  control subjects; open circles  patients with AF. *p
 0.05 vs. control subjects.
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the reverse-rate dependency of sotalol was lost in patients
with AF. Furthermore, sotalol further impaired the rate
adaptation of atrial refractoriness in patients with AF.
These changes in the electrophysiologic actions of dl-sotalol
in the remodeled atrium might account for its limited
efficacy to prevent induction of secondary AF in the major-
ity of patients with AF.
Previous experimental studies have demonstrated that
AF-related atrial remodeling affects the anti-arrhythmic
drug actions. Li et al. (22) have reported a marked differ-
ences in the effects of the class III agent dofetilide in
different animal models of sustained AF. Sato et al. (23)
have also demonstrated that tachycardia-induced remodel-
ing significantly attenuated the prolongation of atrial refrac-
toriness by the class IC agent pilsicainide. The exact
mechanism for the changes in the electrophysiologic action
of dl-sotalol in the remodeled atrium remains unclear.
There are several potential mechanisms in which AF-
related ionic remodeling could alter the electrophysiologic
actions of dl-sotalol (24). If the ionic current or channel
against which a drug is targeted is reduced by remodeling,
the drug would be expected to have a limited effect on the
action potential. Recent studies have demonstrated that the
amount of messenger ribonucleic acid and/or protein ex-
pression of HERG decreased in goats (25) and patients with
persistent AF (26,27). This ionic remodeling may reduce
the sensitivity of the atrial myocytes to dl-sotalol. Further-
more, the changes in the action potential profile caused by
atrial remodeling can reduce the response to sotalol. It has
been postulated that only a small amount of IKr is activated
during the short plateau of the AF-related remodeled action
potential (28). As a result, prolongation of atrial refractori-
ness produced by IKr blockage with sotalol would be
reduced. Whether reversal or prevention of the AF-induced
electrical remodeling and ionic remodeling after restoration
and maintenance of sinus rhythm (5,6), or by using other
agents, such as calcium channel blockers (29,30), restores
the electrophysiologic actions of dl-sotalol in the atrium and
improves its efficacy in preventing AF requires further study.
Study limitations. This study has several limitations. First,
the ERP was measured only at one site in the HRA and one
site in the DCS; therefore, the effects of sotalol on refrac-
toriness in other areas of the atrium or on the heterogeneity
of refractoriness remain unknown. Second, patients with a
diseased atrium but without AF were not included in this
study. Whether the observed effects of sotalol in patients
with AF are related to the presence of AF or the diseased
atrium is unclear. Third, the monophasic action potential
was not recorded in this study, and the action potential
duration could not be measured. The use of monophasic
action potential recordings, together with ERP measure-
ments, might provide a better insight into the true mechanism
of the effects of sotalol in the remodeled atrium. Finally,
only the short-term effect of sotalol immediately after
cardioversion was investigated in this study. The long-term
effect of sotalol in the remodeled atrium remains unknown.
Conclusions. The electrophysiologic actions of dl-sotalol
change significantly in the remodeled atrium of humans and
limit its efficacy in preventing AF recurrence early after
cardioversion. Recent clinical studies have suggested that
pretreatment with calcium channel blockers, such as vera-
pamil, to attenuate AF-induced remodeling before cardio-
version may provide a synergistic effect with other anti-
arrhythmic agents, thus preventing AF recurrence (7,31).
Therefore, future anti-arrhythmic therapy for AF may need
to target not only the atrial electrophysiologic properties,
per se, but also the changes in atrial electrophysiology
resulting from AF-induced remodeling.
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